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Impact of polymorphisms in the genes encoding xylosyltrans-
ferase I and a homologue in type 1 diabetic patients with and
without nephropathy.
Background. Xylosyltransferase I (XT-I) is the chain-
initiating enzyme in the biosynthesis of heparan sulfate proteo-
glycans (HSPGs). It catalyses the transfer of xylose to specific
serine residues in the core protein. The XYLT-II gene codes for
a protein highly homologous to the XT-I but its biologic func-
tion is not yet known. HSPGs are thought to play an important
role in the permeability properties of the glomerular basement
membrane (GBM) and thus the xylotransferase genes might be
potential candidate genes predisposing to diabetic nephropathy
in type 1 diabetic patients.
Methods. We screened all XYLT-I and XYLT-II exons and
flanking intron regions in 96 Caucasians with type 1 diabetes (48
with and 48 without diabetic nephropathy) using denaturing
high-performance liquid chromatography (DHPLC). We also
studied a nondiabetic control group.
Results. Applying this technique we identified 13 variations
in XYLT-I and 20 in XYLT-II. The variations IVS6-9T>C
and IVS6-14 IVS6-13insG in XYLT-II were found with a fre-
quency of 5.2% (5/96) in nondiabetic nephropathy patients,
while all nephropathy patients were negative (P = 0.06). Non-
diabetic controls also showed the single nucleotide polymor-
phisms (SNP) at a frequency of 1.1% (5/440). The investigation
of the SNPs’ influence on clinical characteristics revealed sig-
nificant associations for c.1989T>C (XYLT-I) and c.2402C>G
(XYLT-II) with patients’ blood pressure.
Conclusion. We detected in our cohort associations between
DNA sequence variations of genes encoding xylosyltransferases
and the occurrence of altered clinical characteristics.
Key words: type 1 diabetes, diabetic nephropathy, heparan sulfate
proteoglycans, xylosyltransferase, genetic variations, polymorphisms,
SNPs, DHPLC.
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Diabetic nephropathy is a major cause of morbidity and
mortality in patients with type 1 diabetes [1]. It affects ap-
proximately one third of patients with type 1 diabetes and
peak onset is within 10 to 20 years of the duration of di-
abetes [1, 2]. The pathogenesis of diabetic nephropathy
seems to be multifactorial. The duration of diabetes mel-
litus, tightness of glycaemic control, hypertension, and
hereditary factors are suggested to be implicated in the
pathogenesis of diabetic nephropathy, although the pre-
cise molecular mechanisms remain unclear [3, 4]. The ge-
netic involvement in the etiology of diabetic nephropathy
is believed to be polygenic [4].
Recent studies indicate that alterations in glomeru-
lar proteoglycan structure, content and metabolism can
play an important role in the pathogenesis of diabetic
nephropathy [5, 6], leading to an increase in the thick-
ness and decrease in the density of anionic sites in the
glomerular basement membrane (GBM) and at least to
an increased permeability of albumin [5, 7]. The highly
anionic heparan sulfate proteoglycan (HSPG) is an im-
portant constitutional component of the GBM and re-
sponsible for the size- and charge-selective aspects of the
glomerular passage of macromolecules [8, 9]. The loss
of heparan sulfate negative charges may depend on de-
creased glycosaminoglycan (GAG) chain addition, elon-
gation or sulfation, or an increased GAG degradation
[10]. Furthermore, diabetic nephropathy leads to a re-
duction of the content of HSPG in the GBM without an
apparent decrease in the HSPG core protein expression
[6, 7].
HSPGs are ubiquitous macromolecules associated
with the extracellular matrix (ECM). The basic HSPG
structure consists of a protein core to which several lin-
ear heparan sulfate chains are covalently attached [11].
To date, three HSPG core proteins, perlecan, agrin, and
collagen XVIII have been identified in the GBM [12, 13].
Agrin is that most abundantly expressed HSPG in the
GBM [14].
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The glycosylation of core proteins in heparan sulfate,
heparin, chondroitin sulfate, and dermatan sulfate con-
taining proteoglycans is initiated by xylosyltransferase I
(XT-I) (EC 2.4.2.26). XT-I catalyses the transfer of xy-
lose from uridine diphosphate (UDP)-xylose to selected
serine residues in the proteoglycan core protein. This is
the initial and apparently rate-limiting step in the for-
mation of the common tetrasaccharide linkage region
(-GlcA-Gal-Gal-Xyl-Ser-) to which many disaccharide
repeats are attached as part of the biosynthesis of PGs
[15]. The heparan sulfate side chain is unbranched and
consists of up to 150 disaccharide units of alternating N-
acetyl-glucosamine and glucuronate residues. The disac-
charide elongation of the linker is followed by extensive
modifications of heparan sulfate-GAG through a variety
of different enzymes. This leads to the presence of highly
negative charged sulfate- and carboxyl-groups [16–18].
The XYLT-II gene codes for a protein highly homolo-
gous to the XT-I. The C-terminal regions of both proteins,
where the catalytic domain was found to be located in
glycosyltransferases, are highly conserved [19–21]. These
findings led us to conclude that the XYLT-II gene en-
codes another xylosyltransferase, although the catalytic
activity and the biologic function of XT-II are not yet
known [19]. HSPGs are thought to be an important deter-
minant for the permeability properties of the GBM. The
observed decrease in HSPGs in diabetic nephropathy
without changes in the core protein expression [6, 7] in-
dicates that the homeostasis of the GBM depends on
the catalytic function of enzymes involved in the HSPG
biosynthesis. Therefore abnormalities of the xylosyltrans-
ferase genes may predispose to diabetic nephropathy. The
gene for XYLT-I is located on chromosome 16p13.1, con-
sists of 12 exons and extends over 300 kbp. In contrast the
XYLT-II gene is localized on chromosome 17q21.3-22,
comprises 11 exons and spans only 15 kbp. The XYLT-I
gene is 20-fold larger than the XYLT-II gene but the
exon/intron structure of both genes is highly conserved.
The results indicate that the two genes have descended
from a common xylosyltransferase gene.
The present study was carried out to comprehensively
investigate the role of XT-I and XT-II in conferring ge-
netic susceptibility to type 1 diabetes and to diabetic
nephropathy in type 1 diabetic patients. Until now, no
disease-associated sequence variations in the xylosyl-
transferase genes were known. This is the first systematic
mutational analysis for genetic variations in these genes.
METHODS
Subjects
We investigated DNA samples from 96 patients with
type 1 diabetes mellitus, 48 with and 48 without diabetic
nephropathy from the Steno Diabetes Center, Gentofte,
Denmark (clinical characteristics are shown in Table 1).
Table 1. Clinical characteristics of Caucasian type 1 diabetic patients
with or without diabetic nephropathy
Nephropathy Normoalbuminuria P value
Number 48 48 —
Gender (male/female) 29/19 22/26 0.16
Age years 41.1 ± 11.2 51.8 ± 14.9 <0.01
Duration of diabetes
years
27 ± 9 32 ± 12 0.03
Retinopathy
None 1 (2%) 47 (98%) —
Simplex 9 (19%) 1 (2%) —
Proliferative 38 (79%) — —
Systolic blood pressure
mm Hg
141 ± 17 130 ± 17 <0.01
Diastolic blood
pressure mm Hg
81 ± 12 72 ± 9 <0.01
Hemoglobin A1c% 9.0 ± 1.3 8.1 ± 1.1 <0.01
Urinary albumin
excretion mg/24
hours
849 (34-4965) 5 (2-23) <0.01
Serum creatinine
lmol/L
109 (57-537) 80 (58-104) <0.01
Data are means ± SD, median (range) for the nonnormally distributed
parameters (urinary albumin excretion and serum creatinine) or number.
Further, we analyzed 104 to 240 DNA samples of a non-
diabetic control group (number of controls investigated
was dependent on the localization of the polymorphism)
with 44.7% males and a mean age of 39.7 ± 19.3 years.
The type 1 diabetic patients included in this study were
clinically examined at the Steno Diabetes Center in 1993.
Diabetic nephropathy was manifested if the following cri-
teria were fulfilled: persistent albuminuria of ≥300 mg/
24 hours in at least two of three consecutive 24-hour urine
collections, presence of retinopathy, and no clinical or lab-
oratory evidence of kidney or renal tract disease other
than diabetic glomerulosclerosis [22–24].
The experimental design was approved by the local
ethics committee, and all patients gave their informed
consent.
Polymorphism screening and genotyping
To identify DNA polymorphisms the exons of the xylo-
syltransferase genes were divided into <500 bp fragments
and amplified from genomic DNA by polymerase chain
reaction (PCR). The used primers were located in the
flanking introns to amplify DNA fragments encompass-
ing the exon/intron boundaries and the exon. PCR was
performed in a 50 lL reaction volume, containing ap-
proximately 65 ng genomic DNA, 25 pmol of each primer
(Invitrogen, Leek, The Netherlands), 1.5 U HotStar Taq
(Qiagen, Hilden, Germany) in 1× PCR buffer supplied
with the enzyme and 0.25 mmol/L of each deoxynu-
cleoside triphosphate (dNTP) (Promega, Madison, WI,
USA). The primer sequences, annealing temperatures
and sizes of the PCR products are summarized in Table 2.
The PCR conditions were as follows: initial denaturation
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Table 3. Summary of all detected variations in XT-I and XT-II, their effect on the amino acid sequence and their location in the gene
XT’-Ia XT-IIb
Polymorphism rs number Amino acid Region Genotyping Polymorphism rs number Amino acid Region Genotyping
IVS1-5C>G 5′-UTR DHPLC IVS1-86delG 5′-UTR ND
c.343G>T p.A115S exon 1 Tsp45Ic IVS1-84G>A rs 9912067 5′-UTR ND
c.1077C>T exon 4 PmaCIc IVS1-72G>C rs 9912258 5′-UTR ND
IVS4+47A>G rs 11075341 intron 4 ND IVS1-35G>C 5′-UTR ND
c.1154C>T p.P385L exon 5 DHPLC c.166G>A p.D56N exon 2 Eco47Ic
c.1284C>G exon 5 DHPLC c.177A>G rs 739990 exon 2 BsaWId
IVS8-3G>A intron 7 DHPLC c.342T>C rs 739989 exon 2 BsaWId
c.1875G>A exon 9 DHPLC c.359G>A p.R120H exon 2 DHPLC
c.1883G>A p.R628H exon 9 BsgIc c.453C>T exon 2 DHPLC
c.1989T>C rs 12708815 exon 9 DHPLC c.556G>A p.A186T exon 2 DHPLC
c.2631C>T exon 12 DHPLC c.693G>A exon 3 DHPLC
c.2675G>A p.R892Q exon 12 DHPLC c.914C>G rs 12451299 p.T305R exon 4 Bsu36Id
c.2766G>C exon 12 DHPLC IVS6-9T>C intron 5 Sequencing
IVS6-14 IVS6-13insG intron 5 MwoId
c.1253C>T p.P418L exon 6 BfuAId
IVS7+81A>C intron 7 ND
c.1569C>T rs 4794136 exon 8 MsIId
c.2379G>A exon 11 DHPLC
c.2391C>T exon 11 DHPLC
c.2402C>G rs 6504649 p.T801R exon 11 DHPLC
Abbreviations are: UTR, untranlated region; DHPLC, denatured high-performance liquid chromatography; ND, not determined; rs, number according to data bank.
Mutation numbering refers to the cDNA sequences with the A of the ATG translation initiation start site as nucleotide +1.
aNumbering of the XT-I variations are based on human cDNA sequence (GenBank accession number NM 022166).
Sequence discrepancies between the cDNA and the genomic DNA (GenBank accession numbers AC109446, AC099494, AC009152, AC109495) exist. We detected
in our samples at the following positions only the nucleotide of the genomic sequence:
IVS1-14: g; c.489: c; c.2850: g; c.2853: a.
bNumbering of the XT-II variations is based on human cDNA sequence (GenBank accession number NM 022167).
cMBI Fermentas.
dNew England BioLabs.
at 95◦C for 15 minutes, followed by 35 cycles of denatura-
tion at 94◦C for 1 minute, annealing at fragment-specific
temperature (Table 2) for 1 minute, extension at 72◦C for
1 minute, and a final extension at 72◦C for 15 minutes. De-
natured high-performance liquid chromatography (DH-
PLC) analysis was carried out on an automated HPLC
device equipped with a DNA separation column (Wave
System) (Transgenomic, Omaha, NE, USA). This method
allows the identification of DNA alterations on the basis
of different elution patterns of homo- and heteroduplex
DNA from the column. Therefore, amplicons of the same
fragments from a type 1 diabetic patient and a healthy
subject, whose wild-type sequence (see Table 3) was con-
firmed by double-stranded sequencing, were mixed in a
ratio of 1:1. Heteroduplex formation was induced during
a denaturing (94◦C for 5 minutes) and gradual renaturing
cycle (94◦C to 8◦C over a period of 40 minutes). The mix-
ture was applied to a DNAsept column (Transgenomic)
at a flow rate of 0.9 mL/min by means of a linear acetoni-
trile gradient. The mobile phase consisted of a mixture of
0.1 mol/L triethylamine acetate (pH 7.0) with (buffer B)
or without (buffer A) 25% acetonitrile. The gradient pa-
rameters and optimal analysis temperature for each melt-
ing domain of the amplicon were determined using the
Transgenomic Wavemaker software. Oven temperatures
and the initial and final concentrations of buffer B for
DHPLC analysis are also given in Table 2. Elution pat-
terns of the mixed samples were compared with those of
the wild-type. Samples with an elution profile which dif-
fers from the wild-type were analyzed by DNA sequenc-
ing. PCR and direct sequencing were repeated whenever
a DNA variation was identified in order to exclude the
possibility of amplification errors resulting from HotStar
Taq DNA polymerase. DNA sequencing of PCR prod-
ucts was performed on an Applied Biosystems 310 capil-
lary sequencer using the Big Dye Terminator version 1.1
cycle sequencing kit (Perkin Elmer Applied Biosystems,
Foster City, CA, USA). Based on their location and po-
tential effect on gene function 27 variations (11 of XT-I
and 16 of XT-II) were initially genotyped in type 1 di-
abetic patients and in a nondiabetic control group by
DHPLC or restriction fragment length polymorphism
(Tables 3 and 4). The restriction enzymes were obtained
from New England Biolabs (Beverly, MA, USA) and
from MBI Fermentas (St. Leon-Rot, Germany) and di-
gestions were performed according to the manufacturer’s
instructions.
Statistical analysis
The distribution of the alleles of each single nu-
cleotide polymorphisms (SNP) was tested for the Hardy-
Weinberg equilibrium. Fisher’s two-tailed exact p test
was used to compare allele frequencies between case
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Table 4. Allele frequencies of XT variations in type 1 diabetic patients, nondiabetic control subjects, and type 1 diabetic patients distinguished
between patients with nephropathy and normoalbuminuria
P value P value
Nephropathy Normoalbuminuria Nephropathy vs. Nondiabetic controls Diabetic patients vs.
SNP N = 48 N = 48 normoalbuminuria 104 ≤ n ≤ 240a nondiabetic controls
XT-I IVS1-5C>G 11/96 14/96 0.67 ND ND
c.343G>T 3/96 3/96 1.0 7/208 1.0
c.1077C>T 4/96 3/96 1.0 10/224 0.81
c.1154C>T 0/96 1/96 1.0 2/392 1.0
c.1284C>G 14/96 16/96 0.84 70/392 0.56
IVS8-3G>A 0/96 2/96 0.50 0/408 0.10
c.1875G>A 1/96 0/96 1.0 0/226 0.46
c.1883G>A 0/96 1/96 1.0 0/480 0.29
c.1989T>C 36/96 37/96 1.0 78/226 0.48
c.2631C>T 19/96 13/96 0.33 69/394 0.73
c.2675G>A 1/96 0/96 1.0 1/394 0.55
c.2766G>C 0/96 1/96 1.0 0/394 0.33
XT-II c.166G>A 2/96 1/96 1.0 9/442 1.0
c.177A>G+c.342T>C 75/96 71/96 0.61 168/218 0.82
c.359G>A 1/96 2/96 1.0 0/398 0.03
c.453C>T 0/96 1/96 1.0 0/394 0.33
c.556G>A 0/96 1/96 1.0 0/394 0.33
c.693G>A 1/96 0/96 1.0 0/220 0.47
c.914C>G 75/96 70/96 0.50 172/218 0.48
IVS6-9T>C+ 0/96 5/96 0.06 5/440 0.18
IVS6-14 IVS6-13insG
c.1253C>T 1/96 0/96 1.0 5/230 0.23
c.1569C>T 59/96 49/96 0.19 117/222 0.49
c.2379G>A 1/96 0/96 1.0 0/386 0.33
c.2391C>T 1/96 0/96 1.0 0/386 0.33
c.2402C>G 41/96 36/96 0.56 155/386 1.0
ND is not determined.
aNumber of controls investigated was dependent on the localization of the polymorphism.
subjects and controls. For normally distributed clini-
cal characteristics, a comparison between the groups
was performed by an unpaired Student t test. For non-
normally distributed variables a Mann-Whitney U test
was used. P values of ≤ 0.05 were considered statisti-
cally significant. The haplotype estimation was carried
out using the Estimation Haplotype program (EH-plus)
(ftp://linkage.rockefeller.edu/software/eh) [25, 26].
RESULTS
Mutational screening
With the intention to search for genetic defects in
the XYLT-I and XYLT-II genes that contribute to the
development of type 1 diabetes mellitus and diabetic
nephropathy we screened all 23 exons, exon/intron junc-
tions and parts of the 5′ and 3′ untranslated regions of
these genes. In total 9.4 kbp were screened in each indi-
vidual. This mutational analysis revealed a total of 33 dif-
ferent sequence variations, 13 variations in XYLT-I and
20 in XYLT-II (Table 3). Nine of these variations were
also deposited in the data banks (http://www.ensembl.org
[27] and http://snpper.chip.org [28]) and the rs numbers
are indicated in Table 3. The other 24 variations were
unknown until now. The detected variations included a
single nucleotide deletion in the 5′ untranslated region
and an insertion in the intron 5 of XT-II. All others were
single SNPs: 4 in the 5′ untranslated region, 4 intron vari-
ations, 13 synonymous, and 10 missense variations in the
coding regions. The allele frequencies of the 27 genotyped
DNA alterations (26 SNPs and the insertion) in diabetic
nephropathy and nondiabetic nephropathy patients and
in the nondiabetic control group are shown in Table 4.
Genotype distributions for the 27 variations studied in
our population were in Hardy-Weinberg equilibrium.
Comparison between diabetic nephropathy and
nondiabetic nephropathy patients
The comparison of the allele frequencies between dia-
betic nephropathy and nondiabetic nephropathy patients
in XYLT-I and XYLT-II shows no statistically significant
differences for any of these 27 SNPs (Table 4). Only the
variations in intron 6 of XYLT-II (IVS6-9T>C and IVS6-
14 IVS6-13insG) had the tendency to be different in these
groups (P = 0.06).
We determined and compared the estimated haplotype
frequencies of the most frequent SNPs (>5% allele fre-
quency) in XYLT-I (IVS1-5, c.1284, c.1989, and c.2631)
and XYLT-II (c.177, c.342, c.914, c.1569, and c.2402) in
diabetic nephropathy and nondiabetic nephropathy sub-
jects. The distribution of the haplotypes was similar be-
tween the cases and the controls (data not shown).
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Table 5. Significant clinical characteristics of type 1 diabetic patients with nephropathy or normoalbuminuria according to the genotypes of
selected xylosyltransferase single nucleotide polymorphisms (SNPs)a
Type 1 diabetic patients with nephropathy (N = 48) Type 1 diabetic patients with normoalbuminuria (N = 48)
Parameter Values and occurence Parameter Values and occurence
XT-I
c.343G>T; p.A115S Systolic blood pressure
GG mm Hg 127.2 ± 2.0 (N = 45)
GT 168.2 ± 6.7 (N = 3)
P value <0.01
c.1077C>T Urinary albumin excretion
CC mg/24 hours 928.3 ± 120.5 (N = 44)
CT 2032.0 ± 980.9 (N = 4)
P value 0.03
c.1989T>C Diastolic blood pressure Diastolic blood pressure
TT mm Hg 85.1 ± 2.9 (N = 20) mm Hg 74.9 ± 1.5 (N = 21)
TC+CC 77.7 ± 1.8 (N = 28) 69.0 ± 1.8 (N = 27)
P value 0.03 0.02
XT-II
c.177A>G+c.342T>C Diastolic blood pressure
AA/TT mm Hg 101.5 ± 8.5 (N = 2)
AG/TC+GG/CC 79.9 ± 1.6 (N = 46)
P value 0.01
c.914C>G; p.T305R Creatinine
CC Diastolic blood pressure 101.5 ± 8.5 (N = 2) lmol/L 62.0 ± 4.0 (N = 2)
CG+GG mm Hg 79.9 ± 1.6 (N = 46) 81.2 ± 1.5 (N = 46)
P value 0.01 0.01
c.1569C>T Urinary albumin excretion
CC mg/24 hours 5.2 ± 1.2 (N = 9)
CT+TT 7.4 ± 0.7 (N = 39)
P value 0.05
c.2402C>G; p.T801R HbA1c Systolic blood pressure
CC % 8.4 ± 0.2 (N = 16) mm Hg 123.1 ± 3.3 (N = 18)
CG+GG 9.2 ± 0.2 (N = 32) 133.7 ± 3.1 (N = 30)
P value 0.04 0.03
HbA1c is hemoglobin A1c. Data are mean ± SEM.
aAll not shown SNPs are not significant.
Comparison between all type 1 diabetes mellitus patients
and the nondiabetic controls
The comparison of the allele frequencies between all
type 1 diabetic patients and the nondiabetic control group
(Table 4) shows only for the nonsynonymous variation
c.359G>A (p.R120H) in exon 2 of XYLT-II a higher mu-
tant allele frequency in diabetic patients (P = 0.03). All
other SNPs have no significant differences in the two in-
vestigated groups.
Genotype-phenotype correlation in type 1 diabetes
mellitus patients
In order to analyze the implication of the discov-
ered SNPs with specific phenotypes we investigated se-
lected clinical parameters and the appearance of mu-
tant genotypes. Therefore, we analyzed whether these
phenotypes differ in mutant and wild-type allele carri-
ers in diabetic nephropathy and nondiabetic nephropa-
thy patients. This comparison reveals significant associ-
ations for seven different SNPs (c.343G>T, c.1077C>T,
and c.1989T>C in XYLT-I and c.177A>G+c.342T>C,
c.914C>G, c.1569C>T, and c.2402C>G in XYLT-
II). They result in different diastolic blood pressure,
hemoglobin A1c (HbA1c), and urinary albumin exre-
tion rate in diabetic nephropathy patients and in differ-
ent systolic blood pressure, diastolic blood pressure, uri-
nary albumin exretion rate, and creatinine in nondiabetic
nephropathy patients (Table 5).
DISCUSSION
The impairment of glomerular filtration in diabetic
nephropathy depends on alterations in the GBM [5–7].
The decrease in HSPGs negative charges let us suppose
that enzymes responsible for the homeostasis of the GBM
are involved in the pathogenesis of diabetic nephropa-
thy. We performed mutational screening of the XYLT-I
and XYLT-II genes in order to analyze whether varia-
tions in these genes influence the development of diabetic
nephropathy in type 1 diabetes mellitus. In the present
study, we revealed a total of 33 different XYLT-I and
XYLT-II variations. Most of the sequence variations in
the exons are neutral, only ten SNPs change the corre-
sponding amino acid sequence. We did not find deletions,
insertions or nonsense mutations in the exons that re-
sulted in truncated proteins. These results suggest that
the function of the xylosyltransferases is essential for life
as proteoglycans are involved in many central physiologic
processes.
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All detected SNPs in diabetic nephropathy and nondia-
betic nephropathy patients occur with similar frequencies
and there is no statistical evidence of association with the
development of diabetic nephropathy and genetic varia-
tions in the analyzed XYLT regions. The problem of sta-
tistical analysis is the low frequency of 17 SNPs (<5%).
Eleven of these rare SNPs were unique in nephropathy
or normoalbuminuria patients, making it difficult to as-
sess the connection between these SNPs and type 1 di-
abetes. Interestingly, the intron variations IVS6-9T>C
and IVS6-14 IVS6-13insG in XYLT-II were only found
together and only in nondiabetic nephropathy patients
with a frequency of 5.2% (P = 0.06). They were not
proved in patients with nephropathy, but they were also
detected in the nondiabetic controls with a frequency
of 1.1%. These variations affect the 3′ splice site (IVS6-
9T>C) and the branch site (IVS6-14 IVS6-13insG) [29,
30, 31] and may play a potential role for mRNA splicing.
The T to C exchange would not influence the recogni-
tion because the consensus sequence for this position is a
pyrimidine [29]. The insertion of the nucleotide G shifts
the following bases and changes the splice signal in the
branch site. The effect of the changed splicing signal on
the RNA splicing effiency is difficult to predict because
the rules for splicing are complex and multiple degen-
erated motifs are involved [30]. Consequently, it might
be useful to analyze these variations in other groups to
investigate if they have a protective effect on the devel-
opment of diabetic nephropathy. Furthermore, biochem-
ical in vitro assays [31] for the assessment of pre mRNA
splice efficiency could be used to shed light on the con-
sequences of this alteration in the XYLT-II nucleotide
sequence. Allele frequencies of SNPs with >5% were
not found to be significantly different between diabetic
nephropathy and nondiabetic nephropathy patients, indi-
cating that they are not associated with the development
of diabetic nephropathy in type 1 diabetic patients. The
distribution of the haplotypes was also similar between
the diabetic nephropathy and nondiabetic nephropathy.
The four most frequent SNPs in XYLT-I (IVS1-5C>G,
c.1284C>G, c.1989T>C, and c.2631C>T) result in 12 of
16 possible haplotypes which vary in order of frequencies
and haplotypes occurred in these two groups. In XYLT-II
four haplotypes predominated and they account together
in cases for 100% and in controls for 98%. It seems
that the SNPs c.177A>G and c.342T>C in exon 2 of
XYLT-II are inherited together because only wildtype or
only mutant alleles appeared and no mixed genotype was
detected.
The nonsynonymous SNP c.359G>A (p.R120H) in
exon 2 of XYLT-II had a low A allele frequency (3/192) in
type 1 diabetic patients and was only found in heterozy-
gous state, all control subjects were negative for the men-
tioned variation (0/398). Although this SNP occur with
significant differerent frequencies (P = 0.03) it has no
etiologic or clinical relevance because of the low appear-
ance. Furthermore, the biologic function of XT-II remains
unclear and so it is difficult to evaluate the amino acid
exchange. XT-II is a type 2 transmembrane protein and
exon 2 probably codes for the stem region of this protein.
To what extent the altered amino acid has an influence on
the conformation or the biologic function of the protein
will have to be investigated after the enzymatic function
of XT-II has been clarified. Nine variations with a fre-
quency under 5% (four in XYLT-I and five in XYLT-II
(without c.359G>A)) were only discovered in diabetic
patients. It should be noted that the low allele frequency
and the small cohort size render the evaluation of the sig-
nificance of low frequent SNPs difficult. But these rare or
unique SNPs do not play a major role in the development
of diabetic nephropathy or type 1 diabetes. The allele fre-
quencies of SNPs with >5% occurred equally in diabetic
patients and the nondiabetic controls.
The evaluation of the detected genotype-phenotype
correlations is only meaningful for the SNPs c.1989C>T
in XYLT-I and c.2402C>G in XYLT-II because only for
these both a reasonable number of mutant allele carri-
ers is available. For the other interactions the number of
patients is too small for a valid interpretation. Diabetic
nephropathy and nondiabetic nephropathy patients with
the mutant allele of the neutral SNP c.1989T>C in exon 9
of XYLT-I have significantly lower diastolic blood pres-
sures in comparison to those diabetic nephropathy and
nondiabetic nephropathy patients carrying the wild-type
allele. The P values are 0.03 for nephropathy patients
and 0.02 for normoalbuminuria patients. The mutant al-
lele c.2402C>G in exon 11 of XYLT-II, which results in
the amino acid exchange p.T801R, is associated with an
elevated systolic blood pressure in normoalbuminuria pa-
tients (P = 0.03). Both of these SNPs have a frequency
of over 5% and were found in homo- and heterozygous
state. These xylosyltransferase variations are suggested
to affect blood pressure as HSPGs are also components
of the vascular endothelial cells, and alterations in the
proteoglycan metabolism can also have a negative effect
on blood vessel structure and flexibility. Therefore, the
importance of the SNPs’ influence on clinical parameters
and the patients’ prognosis should be examined in further
studies.
CONCLUSION
The first systematic mutation scanning of the human
xylosyltransferase genes identified no variations which
were significantly associated with the development of di-
abetic nephropathy in type 1 diabetes mellitus patients.
The two variations in the intron of XYLT-II show the
tendency (P = 0.06) to be associated with the develop-
ment of diabetic nephropathy in type 1 diabetic patients.
The missense variation c.359G>A (p.R120H) in exon 2 of
1490 Scho¨n et al: XYLT polymorphisms and diabetic nephropathy
XYLT-II shows a significant association between type
1 diabetic patients and the nondiabetic control group.
These findings should stimulate further investigations on
the role of these SNPs in the pathogenesis of type 1 di-
abetes and diabetic nephropathy. Further, we detected
significant associations between the blood pressure and
the appearance of mutant alleles for two SNPs. These as-
sociations need to be validated in additional, large mul-
ticenter case-control studies.
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